This article was originally published in SRA
Industry and health groups to challenge EU directive in the ECJ
You may also be interested in...
Legal experts explain why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
Ex-Novartis executive and co-founder of investment bank MM Dillon & Co shares insights around where healthcare unicorns can be found and some core criteria to build such firms.
In this week's podcast edition of Scrip's Five Must-Know Things, hear about Sanofi’s rebates, Moderna’s business prospects, US views on coronavirus vaccine comparisons, Piot talk about virus variants, and new results for Amgen's asthma drug.